Physician profile
Christopher Walcott
NPI 1386931137
$355.36
in general payments reported to CMS, 2019-2025
14 companies · $46.62 in 2025
The $46.62 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $255 · 2020: $38.97 · 2022: $14.29 · 2025: $46.62.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $46.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $46.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $73.43 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $46.99 | 2019-2020 | |
| Csl Behring | $30.94 | 2019 | |
| Allergan, INC. | $28.82 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $25.36 | 2019 | |
| Pfizer INC. | $25.36 | 2019-2020 | |
| Lilly USA, LLC | $21.74 | 2019 | |
| Mdd US Operations, LLC | $16.53 | 2019 | |
| Astellas Pharma US INC | $16.33 | 2025 | Veozah |
| Abbvie INC. | $15.86 | 2025 | |
| Amgen INC. | $14.43 | 2025 | Otezla, Repatha |
| Abbott Laboratories | $14.29 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.66 | 2019 | |
| Shire North American Group INC | $12.62 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Walcott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.